<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the feasibility of maintaining specific plasma concentrations of ara-C and <z:chebi fb="0" ids="4911">VP-16</z:chebi> in children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Sixty-one children were treated with 6 sequential cycles of intensive chemotherapy consisting of: (1) <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-C)/<z:chebi fb="0" ids="4911">VP-16</z:chebi>, (2) ara-C/<z:chebi fb="0" ids="41977">daunorubicin</z:chebi> (Dauno), (3) <z:chebi fb="0" ids="4911">VP-16</z:chebi>/<z:chebi fb="0" ids="2687">amsacrine</z:chebi> (m-AMSA), (4) <z:chebi fb="0" ids="4911">VP-16</z:chebi>/<z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> (5-Az), (5) ara-C/Dauno, and (6) ara-C/<z:chebi fb="0" ids="4911">VP-16</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-nine children had de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 2 had a previous <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The number of patients with each specific FAB subtype was: M0-1; M1-7; M2-24; M3-7; M4-5; M5-11; and M7-6 </plain></SENT>
<SENT sid="4" pm="."><plain>Simultaneous continuous infusions of ara-C and <z:chebi fb="0" ids="4911">VP-16</z:chebi> (cycle 1) given at individualized doses to achieve drug plasma concentrations of 1 microM and 30 microM, respectively, produced complete remission (CR) in 26 of 61 patients (43%); an additional 17 patients entered CR after Dauno/ara-C (cycle 2), and one patient required 4 cycles of chemotherapy to achieve CR (total CR rate = 72%) </plain></SENT>
<SENT sid="5" pm="."><plain>The preliminary 2-year event-free survival (EFS) for patients with <z:e sem="disease" ids="C0026998" disease_type="Neoplastic Process" abbrv="">FAB-M1</z:e> and -M2 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was only 15% versus 40% for those with <z:e sem="disease" ids="C0023479" disease_type="Neoplastic Process" abbrv="AMML">FAB-M4</z:e> and -M5 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, 21 of the 61 patients remain in CR (2-yr EFS = 29%) </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that intense treatment with ara-C and <z:chebi fb="0" ids="4911">VP-16</z:chebi> at doses individualized to achieve target plasma concentrations is feasible although severely myelosuppressive </plain></SENT>
<SENT sid="8" pm="."><plain>It results in an acceptable CR rate, but does not improve EFS.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>